JANTOVEN Drug Patent Profile
✉ Email this page to a colleague
When do Jantoven patents expire, and when can generic versions of Jantoven launch?
Jantoven is a drug marketed by Upsher Smith Labs and is included in one NDA.
The generic ingredient in JANTOVEN is warfarin sodium. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the warfarin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jantoven
A generic version of JANTOVEN was approved as warfarin sodium by TARO on July 15th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JANTOVEN?
- What are the global sales for JANTOVEN?
- What is Average Wholesale Price for JANTOVEN?
Summary for JANTOVEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 5 |
| Patent Applications: | 5,783 |
| Drug Prices: | Drug price information for JANTOVEN |
| Drug Sales Revenues: | Drug sales revenues for JANTOVEN |
| DailyMed Link: | JANTOVEN at DailyMed |
Recent Clinical Trials for JANTOVEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Nicholas Carlson | Phase 4 |
| Danish Heart Foundation | Phase 4 |
| Daiichi Sankyo, Inc. | Phase 1 |
Pharmacology for JANTOVEN
| Drug Class | Vitamin K Antagonist |
| Mechanism of Action | Vitamin K Inhibitors |
US Patents and Regulatory Information for JANTOVEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-001 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-007 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-004 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-008 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-002 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-003 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
